• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·688117.SS
Share

ChengDu ShengNuo Biotec Co.,Ltd. Stocks

CN¥ 28.47Last Updated 14.07.2026

Issuer Rating

4/7
Performance

Average

Risk

Moderate

Recommendation

Hold

Market Cap

CN¥ 949.85M

CN¥ 28.47
Key Takeaways

Risk factor

High price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable price performance

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

ChengDu ShengNuo Biotec Co.,Ltd. focuses on the entire lifecycle of peptide pharmaceuticals, from initial research and development to manufacturing, and their subsequent domestic and international distribution. The company's product portfolio encompasses active polypeptide ingredients (APIs), solid dosage tablets, and a diverse range of injectable formats, including freeze-dried powders, small-volume solutions, pre-filled syringes, and specialized card-type injections. This enterprise was established in 2001 and conducts its operations from Chengdu, China.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is fairly valued on P/E, overvalued on EV/E

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Slightly negative
3/7

The average target price of 688117.SS is 27.9 and suggests 4.62% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

14.07.2026 18:30

Revolut Will Participate in Testing the Digital Euro

14.07.2026 18:12

Oil at $87, Houthi attacks, strikes on UAE tankers: What’s happening in the Middle East?

14.07.2026 17:48

Consumer inflation in the U.S. turned out to be much lower than expected

14.07.2026 17:40

Nebius closed a $1 billion deal with a startup founded by former Google AI developers

14.07.2026 17:25

SpaceX Lost More Than $800 Billion in Market Value in a Month: Shares Are Close to Their IPO Price

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026